Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCF-12
- Development stage
- Unknown
- Lead developer
- Teijin Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TCF-12 is an investigational oral uremic toxin adsorbent being developed by Teijin Pharma for the treatment of chronic kidney disease (CKD). It is designed to selectively adsorb uremic toxins, such as indoxyl sulfate, within the gastrointestinal tract, thereby preventing their absorption into the systemic circulation. By lowering the levels of these toxins, TCF-12 aims to slow the progression of renal dysfunction and reduce the risk of cardiovascular complications associated with CKD. The drug is currently in Phase 1/2 clinical development in Japan, where it is being compared to placebo and the existing oral adsorbent Kremezin (AST-120).
02
Targets
IS (Indoxyl sulfate)
Beyond the preview
Go deeper on TCF-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCF-12.